Please Wait.....
Report
Diffuse Large B-cell Lymphoma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs), By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies), By End-User (Hospitals & Clinics, Ambulatory care Centers, Others), By Region and Competition, 2020-2030F
Market Report I 2025-03-28 I 183 Pages I TechSci Research
Global Diffuse Large B-cell Lymphoma Therapeutics Market was valued at USD 4.02 Billion in 2024 and is expected to reach USD 6.36 Billion in the forecast period with a CAGR of 7.91% through 2030. The Global Diffuse Large B-cell Lymphoma (DLBCL) Therapeutics Market is experiencing significant growth due to rising incidence rates, advancements in targeted therapies, and increasing awareness about early diagnosis. DLBCL, the most common subtype of non-Hodgkin's lymphoma, has seen a surge in cases, driving demand for effective treatment options. The market is benefiting from the expanding approval of novel therapies, including CAR-T cell treatments, bispecific antibodies, and monoclonal antibodies, which are improving survival rates and offering new hope for patients with relapsed or refractory disease. Pharmaceutical companies and research institutions are actively investing in drug development, leading to a robust pipeline of innovative therapies. The shift toward personalized medicine and biomarker-driven treatment approaches is further revolutionizing the market, enabling tailored therapies that enhance treatment efficacy and reduce adverse effects.
Key Market Drivers
Rising Incidence of Diffuse Large B-cell Lymphoma (DLBCL)
The rising incidence of Diffuse Large B-cell Lymphoma (DLBCL) is a significant driving force behind the growth of the global DLBCL therapeutics market. DLBCL is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 25% to 30% of all NHL cases worldwide. In the United States, the age-standardized incidence rate for DLBCL is 7.2 per 100,000 individuals, with higher rates observed among non-Hispanic whites (9.2 per 100,000). In the United Kingdom, about 5,000 people are diagnosed with DLBCL annually, representing more than 40% of adult NHL cases. This increasing prevalence is a cause for concern and a catalyst for innovative treatment approaches.
Several factors contribute to the escalating incidence of DLBCL. The aging global population is a significant factor, as DLBCL predominantly affects older adults. Most individuals diagnosed with DLBCL are 65 years or older. As life expectancy increases, the number of older individuals at risk for DLBCL rises, thereby expanding the patient population in need of treatment.
Key Market Challenges
High Cost of Innovative Therapies
The high cost of innovative therapies stands as a significant barrier hindering the global Diffuse Large B-cell Lymphoma (DLBCL) therapeutics market. DLBCL, as one of the most common subtypes of non-Hodgkin lymphoma, necessitates cutting-edge treatments to improve patient outcomes. However, the exorbitant prices associated with these therapies create formidable challenges for both patients and healthcare systems.
In recent years, the development of novel treatments, such as Chimeric Antigen Receptor T-cell therapy (CAR-T therapy) and targeted drugs, has provided new hope for DLBCL patients. CAR-T therapy, for instance, involves genetically modifying a patient's T-cells to attack cancer cells specifically. While these therapies offer remarkable results, they often come with a staggering price tag. CAR-T therapies can cost hundreds of thousands of dollars, putting them out of reach for many patients.
Key Market Trends
Immunotherapy Revolution
The immunotherapy revolution is playing a pivotal role in boosting the global Diffuse Large B-cell Lymphoma (DLBCL) therapeutics market. DLBCL, being a prevalent and aggressive subtype of non-Hodgkin lymphoma, has long posed significant challenges for treatment. However, recent breakthroughs in immunotherapy have transformed the landscape of DLBCL therapeutics.
Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, are among the key drivers of this revolution. These drugs work by blocking specific proteins that inhibit the immune system's response to cancer cells. In DLBCL, they have shown promising results by reinvigorating the body's immune defenses against cancer. Patients who have exhausted conventional treatment options, especially those with relapsed or refractory DLBCL, have witnessed remarkable responses to these immunotherapies.
Another groundbreaking immunotherapy approach in DLBCL is Chimeric Antigen Receptor T-cell therapy (CAR-T therapy). CAR-T therapies, like axicabtagene ciloleucel and tisagenlecleucel, involve genetically modifying a patient's own T-cells to express chimeric antigen receptors that target specific proteins on the surface of DLBCL cells. This precise targeting has led to high response rates and prolonged remissions in some patients, even those with refractory disease.
Key Market Players
- Gilead Sciences Inc
- Novartis AG
- Pfizer Inc.
- Merck & Co. Inc.
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd.
- CTI BioPharma Corp.
- Celltrion Healthcare Co. Ltd.
- Bristol Myers Squibb Company
- AbbVie Inc
Report Scope:
In this report, the Global Diffuse Large B-cell Lymphoma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Global Diffuse Large B-cell Lymphoma Therapeutics Market, By Drug Class:
o Cisplatin
o Carboplatin
o 5-fluorouracil
o Docetaxel
o Paclitaxel
o Methotrexate
o Other Drugs
- Global Diffuse Large B-cell Lymphoma Therapeutics Market, By Therapy:
o Targeted Therapy
o Immunotherapy
o Chemotherapy
o Other Therapies
- Global Diffuse Large B-cell Lymphoma Therapeutics Market, By End-User:
o Hospitals &Clinics
o Ambulatory care Centers
o Others
- Global Diffuse Large B-cell Lymphoma Therapeutics Market, By Region:
o North America
United States
Canada
Mexico
o Europe
France
United Kingdom
Italy
Germany
Spain
o Asia-Pacific
China
India
Japan
Australia
South Korea
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Turkey
Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Diffuse Large B-cell Lymphoma Therapeutics Market.
Available Customizations:
Global Diffuse Large B-cell Lymphoma Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Drug Class (Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs)
4.2.2. By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies)
4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
4.2.4. By Region
4.2.5. By Company (2024)
4.3. Market Map
4.3.1. By Drug Class
4.3.2. By Therapy
4.3.3. By End-User
4.3.4. By Region
5. Asia Pacific Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class
5.2.2. By Therapy
5.2.3. By End-User
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Drug Class
5.3.1.2.2. By Therapy
5.3.1.2.3. By End-User
5.3.2. India Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Drug Class
5.3.2.2.2. By Therapy
5.3.2.2.3. By End-User
5.3.3. Australia Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Drug Class
5.3.3.2.2. By Therapy
5.3.3.2.3. By End-User
5.3.4. Japan Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Drug Class
5.3.4.2.2. By Therapy
5.3.4.2.3. By End-User
5.3.5. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Drug Class
5.3.5.2.2. By Therapy
5.3.5.2.3. By End-User
6. Europe Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Therapy
6.2.3. By End-User
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Therapy
6.3.1.2.3. By End-User
6.3.2. Germany Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Therapy
6.3.2.2.3. By End-User
6.3.3. Spain Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Therapy
6.3.3.2.3. By End-User
6.3.4. Italy Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Drug Class
6.3.4.2.2. By Therapy
6.3.4.2.3. By End-User
6.3.5. United Kingdom Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Drug Class
6.3.5.2.2. By Therapy
6.3.5.2.3. By End-User
7. North America Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Therapy
7.2.3. By End-User
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Therapy
7.3.1.2.3. By End-User
7.3.2. Mexico Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Therapy
7.3.2.2.3. By End-User
7.3.3. Canada Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Therapy
7.3.3.2.3. By End-User
8. South America Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Therapy
8.2.3. By End-User
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Therapy
8.3.1.2.3. By End-User
8.3.2. Argentina Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Therapy
8.3.2.2.3. By End-User
8.3.3. Colombia Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Therapy
8.3.3.2.3. By End-User
9. Middle East and Africa Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Therapy
9.2.3. By End-User
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Therapy
9.3.1.2.3. By End-User
9.3.2. Saudi Arabia Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Therapy
9.3.2.2.3. By End-User
9.3.3. UAE Diffuse Large B-cell Lymphoma Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Therapy
9.3.3.2.3. By End-User
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Diffuse Large B-cell Lymphoma Therapeutics Market: SWOT Analysis
13. Porters Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. Competitive Landscape
14.1. Gilead Sciences Inc
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Current Capacity Analysis
14.1.5. Financials (In case of listed)
14.1.6. Recent Developments
14.1.7. SWOT Analysis
14.2. Novartis AG
14.3. Pfizer Inc.
14.4. Merck & Co. Inc.
14.5. GlaxoSmithKline plc
14.6. F. Hoffmann-La Roche Ltd.
14.7. CTI BioPharma Corp.
14.8. Celltrion Healthcare Co. Ltd.
14.9. Bristol Myers Squibb Company
14.10. AbbVie Inc
15. Strategic Recommendations
16. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security